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ABSTRACT 
Tumor growth and metastasis are dependent on angiogenesis that constantly alters the 
tumor microenvironment. Based on the antiangiogenic principle proposed more than 40 
years ago by Dr. Judah Folkman, antiangiogenic drugs (ADs) are successfully 
developed and are routinely used in combination with chemotherapeutics for treatment 
of various cancers in human patients.  However, nearly 10-year clinical experiences 
with these drugs have taught us some unexpected outcomes that are mechanistically 
challenging. These include: 1) Ineffective antiangiogenic monotherapy; 2) Modest 
therapeutic benefits in combination with chemotherapy; 3) Development of intrinsic 
and evasive drug resistance; 4) Broad adverse effects; 5) Timeline of treatment; 6) 
Searching for reliable and predictive biomarkers for patient selection and monitoring 
therapeutic efficacy. Currently, mechanisms underlying these important clinical issues 
remain poorly understood. In this thesis, we aimed to study the mechanisms that 
underlie clinical benefits of ADs, clinical adverse effects related to antiangiogenic 
therapy and interplay between different factors in the tumor microenvironment in 
modulation of tumor growth and drug responses. In the first published paper, we show 
that tumor-derived VEGF enters the circulation and causes a systemic effect by 
alteration of vessels numbers and structures in various tissues and organs. This 
systemic effect, which we term as cancer-associated systemic syndrome (CASS), is 
similar to paraneoplastic syndrome, often seen in cancer patients, manifesting anemia, 
endocrine dysfunction, and hepato-splenomegaly. Based on these findings, we 
hypothesized that treatment of high VEGF-expressing tumors with chemotherapeutics 
that often have hematopoietic suppressive effect would cause severe defects of bone 
marrow hematopoiesis. Indeed, treatment of high VEGF-expressing tumor-bearing 
mice results in severe anemia, leading to early demise of animals. Prior to 
chemotherapy, delivery of antiangiogenic agents markedly prevents chemotherapy-
induced hematopoietic suppression. From this study we conclude: 1) Sequential 
delivery of ADs followed by chemotherapeutics is a preferred regimen; and 2) 
Reduction of chemotoxicity by ADs is, at least in part, a mechanism that underlies 
combination therapy. In the second paper, we show that PlGF, a member of the VEGF 
family, negatively regulates VEGF-induced tumor angiogenesis and tumor growth by 
the formation of PlGF-VEGF heterodimers.  Notably, PlGF-overexpressing mouse and 
human tumors demonstrate superior sensitivity to ADs. Thus, PlGF may potentially be 
used as a surrogate marker to predict antiangiogenic therapy. In the third paper, we 
demonstrated that systemic delivery of ADs to mice causes a broad systemic effect on 
healthy vasculatures in various tissues and organs. These “off-tumor” effects in general 
correlated well with clinical adverse effects of these drugs in cancer patients. Thus 
these findings provide a new mechanistic insight of antiangiogenic therapy-related side 
effects. In the fourth paper, we show a new protocol of studying lymphangiogenesis, 
which is essential for lymphatic metastasis. 
 
 
